TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
Provided By PR Newswire
Last update: Sep 19, 2025
TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease
Read more at prnewswire.com181.62
+1.91 (+1.06%)
Find more stocks in the Stock Screener
JNJ Latest News and Analysis
5 days ago - By: Chartmill
13 days ago - By: Chartmill
